Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
9.65
+0.20 (2.12%)
At close: Jul 16, 2025, 4:00 PM
9.68
+0.03 (0.31%)
After-hours: Jul 16, 2025, 4:00 PM EDT
Forte Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Forte Biosciences stock have an average target of 61, which predicts a 532.12% increase from the current stock price of 9.65.
Price Target: $61 (+532.12%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Forte Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +532.12% | Jun 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $64 → $61 | Strong Buy | Maintains | $64 → $61 | +532.12% | Apr 1, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $64 | Strong Buy | Maintains | $64 | +563.21% | Dec 4, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $3 → $64 | Strong Buy | Maintains | $3 → $64 | +563.21% | Nov 15, 2024 |
Financial Forecast
Revenue This Year
n/a
from 84.85M
Revenue Next Year
n/a
EPS This Year
-5.03
from -12.17
EPS Next Year
-3.69
from -5.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.57 | -3.00 | -2.50 | ||
| Avg | -5.03 | -3.69 | -3.13 | ||
| Low | -5.95 | -4.56 | -3.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.